AI's Breakthroughs in Ovarian Cancer Diagnosis and Treatment

Updated on: June 12,2024

AI's Breakthroughs in Ovarian Cancer Diagnosis and Treatment

Updated on:June 12,2024

FDA warns of counterfeit ozempic

by Dennis ThompsonThe U.S. Food and Drug Administration has uncovered counterfeit Ozempic shots in the legitimate U.S. drug supply chain, and is warning patients to be on their guard.The FDA said Thur

Updated on: January 26,2024

FDA warns of counterfeit ozempic

by Dennis ThompsonThe U.S. Food and Drug Administration has uncovered counterfeit Ozempic shots in the legitimate U.S. drug supply chain, and is warning patients to be on their guard.The FDA said Thur

Updated on:January 26,2024

Simnotrelvir shortens time to resolution of symptoms in COVID-19

by Elana GotkineFor adults with mild-to-moderate COVID-19, early administration of simnotrelvir plus ritonavir shortens the time to sustained resolution of symptoms, according to a study published in

Updated on: March 21,2024

Simnotrelvir shortens time to resolution of symptoms in COVID-19

by Elana GotkineFor adults with mild-to-moderate COVID-19, early administration of simnotrelvir plus ritonavir shortens the time to sustained resolution of symptoms, according to a study published in

Updated on:March 21,2024

Tackling antibiotic resistance when treating pneumonia

JANUARY 18, 2024byUniversity of LiverpoolSchematic summary of the molecular mechanisms in Pseudomonas aeruginosa associated with the observed phenotypic changes in the rabbit model. OprD-associa

Updated on: March 28,2024

Tackling antibiotic resistance when treating pneumonia

JANUARY 18, 2024byUniversity of LiverpoolSchematic summary of the molecular mechanisms in Pseudomonas aeruginosa associated with the observed phenotypic changes in the rabbit model. OprD-associa

Updated on:March 28,2024

Poor trial results may prompt maker to pull ALS drug from market

by Robin FosterFollowing disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market.In astatementissued Friday, Amylyx Pharmaceuticals said t

Updated on: March 20,2024

Poor trial results may prompt maker to pull ALS drug from market

by Robin FosterFollowing disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market.In astatementissued Friday, Amylyx Pharmaceuticals said t

Updated on:March 20,2024

The long—and strange—history of testing menstrual blood for health conditions

by Helen King,The ConversationCredit: public domainThere's good news for anyone who menstruates and doesn't like the needles involved in blood testing. In January 2024, the biotechnology

Updated on: August 06,2024

The long—and strange—history of testing menstrual blood for health conditions

by Helen King,The ConversationCredit: public domainThere's good news for anyone who menstruates and doesn't like the needles involved in blood testing. In January 2024, the biotechnology

Updated on:August 06,2024

Testing found recalled medicine can have a deadly bacterial contamination

by David J. Neal, Miami HeraldCredit: Pixabay/CC0 Public DomainA drug used to treat a form of pneumonia has been recalled after testing found it might be as deadly as the infection it's supposed t

Updated on: April 06,2024

Testing found recalled medicine can have a deadly bacterial contamination

by David J. Neal, Miami HeraldCredit: Pixabay/CC0 Public DomainA drug used to treat a form of pneumonia has been recalled after testing found it might be as deadly as the infection it's supposed t

Updated on:April 06,2024

A new weapon against the super-tough C diff bacteria tested in phase-one human trial

by Laurie Fickman,University of HoustonFecal drug concentrations of omadacycline and vancomycin. Credit:The Journal of Infectious Diseases(2023). DOI: 10.1093/infdis/jiad537In a phas

Updated on: December 30,2023

A new weapon against the super-tough C diff bacteria tested in phase-one human trial

by Laurie Fickman,University of HoustonFecal drug concentrations of omadacycline and vancomycin. Credit:The Journal of Infectious Diseases(2023). DOI: 10.1093/infdis/jiad537In a phas

Updated on:December 30,2023

Researchers identify molecular link between gut bacteria and excitatory brain signaling in C. elegans

by Jim Fessenden, UMass Chan Medical SchoolB12produced by gut bacteria suppresses the hyperactive behavior of unc-2(gof) mutants. Credit:Nature Cell Biology(2024). DOI: 10.1038/s4155

Updated on: January 09,2024

Researchers identify molecular link between gut bacteria and excitatory brain signaling in C. elegans

by Jim Fessenden, UMass Chan Medical SchoolB12produced by gut bacteria suppresses the hyperactive behavior of unc-2(gof) mutants. Credit:Nature Cell Biology(2024). DOI: 10.1038/s4155

Updated on:January 09,2024

Mechanical engineers develop miniaturized, hydrogel-based electric generators for biomedical devices

by The University of Hong KongThe hydrogel electric generator and its working mechanism. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-45931-7Mechanoelectrical energy conversion offers

Updated on: May 14,2024

Mechanical engineers develop miniaturized, hydrogel-based electric generators for biomedical devices

by The University of Hong KongThe hydrogel electric generator and its working mechanism. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-45931-7Mechanoelectrical energy conversion offers

Updated on:May 14,2024

Gene therapy gets a turbo boost from researchers

byUniversity of Hawaii at ManoaGraphical abstract. Credit:Nucleic Acids Research(2024). DOI: 10.1093/nar/gkae534For decades, scientists have dreamed of a future where genetic disease

Updated on: September 03,2024

Gene therapy gets a turbo boost from researchers

byUniversity of Hawaii at ManoaGraphical abstract. Credit:Nucleic Acids Research(2024). DOI: 10.1093/nar/gkae534For decades, scientists have dreamed of a future where genetic disease

Updated on:September 03,2024

ASH: Daratumumab beneficial for patients with multiple myeloma

by Elana GotkineFor transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone inductio

Updated on: January 26,2024

ASH: Daratumumab beneficial for patients with multiple myeloma

by Elana GotkineFor transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone inductio

Updated on:January 26,2024